IFN-α therapy for hepatitis C is associated with a high prevalence of thyroid dysfunction, which is often irreversible. Two studies have recently investigated the role of HCV, PEG-IFN-α and ribavirin in the development of autoimmune thyroid disorders in patients with hepatitis C on antiviral treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Prummel, M. F. & Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 13, 547–551 (2003).
Tomer, Y., Blackard, J. T. & Akeno, N. Interferon alpha treatment and thyroid dysfunction. Endocrinol. Metab. Clin. North Am. 36, 1051–1066 (2007).
Fernandez-Soto, L. et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch. Intern. Med. 158, 1445–1448 (1998).
Antonelli, A. et al. Thyroid disorders in chronic hepatitis C. Am. J. Med. 117, 10–13 (2004).
Antonelli, A. et al. Thyroid disorders in hepatitis C virus chronic infection. Thyroid 16, 563–572 (2006).
Giordano, T. P. et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA 297, 2010–2017 (2007).
Vezali, E., Elefsiniotis, I., Mihas, C., Konstantinou, E. & Saroglou, G. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related? J. Gastroenterol. Hepatol. 24, 1024–1029 (2009).
Jamil, K. M. et al. Interferon-induced thyroid dysfunction in chronic hepatitis C. J. Gastroenterol. Hepatol. 24, 1017–1023 (2009).
Tran, H. A., Attia, J. R., Jones, T. L. & Batey, R. G. Pegylated interferon-a2b incombination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-a2b in a hepatitis C population: meta-analysis. J. Gastroenterol. Hepatol. 22, 472–476 (2007).
Hultgren, C., Milich, D. R., Weiland, O. & Sallberg, M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J. Gen. Virol. 79, 2381–2391 (1998).
Yalowitz, J. A. & Jayaram, H. N. Molecular targets of guanine nucleotides in differentiation, proliferation and apoptosis. Anticancer Res. 20, 2329–2338 (2000).
Antonelli, A. et al. Endocrine manifestations of hepatitis C virus infection. Nat. Clin. Pract. Endocrinol. Metab. 5, 26–34 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Antonelli, A., Ferri, C. & Fallahi, P. Thyroid dysfunction in patients with hepatitis C on IFN-α therapy. Nat Rev Gastroenterol Hepatol 6, 633–635 (2009). https://doi.org/10.1038/nrgastro.2009.168
Issue date:
DOI: https://doi.org/10.1038/nrgastro.2009.168
This article is cited by
-
High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy
Hepatology International (2018)
-
Plasmacytoid dendritic cells are scarcely represented in the human gut mucosa and are not recruited to the celiac lesion
Mucosal Immunology (2013)
-
Environmental triggers of thyroiditis: Hepatitis C and interferon-α
Journal of Endocrinological Investigation (2011)
